Developing First-in-Class Cancer Therapies
At Oxford BioTherapeutics we are dedicated to pioneering the next generation of oncology treatments through targeted therapies, including Antibody-Drug Conjugates (ADC), Immuno-oncology, T-Cell Engagers (TCE), and radiopharmaceuticals.
Our Mission
Transform the Landscape of Cancer Treatment and Improve Patient Outcomes Globally
Oxford BioTherapeutics pioneers next-generation antibody therapies, addressing unmet needs with OGAP®-Verify, a high-sensitivity proteomic platform identifying novel cancer targets. With industry-leading partnerships, OBT advances first-in-class therapies, transforming oncology and expanding treatment options for patients.
The Numbers
Advancing Cancer Treatment Through Strategic Growth
60
60
Partnerships with Key Innovators
30
30
Clinical-Stage Assets
90
90
Partnered Assets
20
20
R&D Sites Across the UK and US
50+0
50+0
Employees
80+0
80+0
Novel, Cancer-Specific Targets Across Cancer Indications
OBT At a glance
Pioneering an Innovative Approach for the Development of First-in-Class Cancer Therapies
We are a dynamic, growing team, bringing together diverse expertise and a shared commitment to innovation, collaboration, and impact—driving progress in cancer treatment through our united purpose and values.
Learn More
Our Workflow
A fully integrated discovery and development workflow from identifying 7,000 membrane proteins in OGAP-Verify® to creating therapeutic antibodies optimised for your needs
7,000 Membrane Proteins Identified and Quantified in OGAP®-Verify
Patient tissue analysed by quantitative membrane proteomics
Novel Membrane Protein Targets Identified for ADC, CAR-T, IO, Radiopharmaceuticals and Bispecific Therapeutic Modalities
Target shortlisting and selection according to partners requirements
Target Validation
Wet bench experiments to confirm the suitability of target for antibody based therapeutics
Generation of Tool Reagents and Models
Therapeutic Antibodies/ Binder Generation, Optimised to Specific Modality
